Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression.

Joanna Szarmach Wiesław Jerzy Cubała Adam Wlodarczyk Maria Gałuszko-Węgielnik

Published in: Neuropsychiatric disease and treatment (2020)

The study demonstrates good safety and tolerability profile of intravenous ketamine as add-on intervention to current psychotropic medication in TRD, regardless of the MDD or BP type of mood disorders. The abatement of elevated RR and BP scores was observed in time with no sequelae nor harm. Still, cardiovascular risks appear to be more pronounced in subjects with comorbid arterial hypertension and diabetes mellitus.

Keyphrases

arterial hypertension
risk factors
pain management
randomized controlled trial
sleep quality
major depressive disorder
bipolar disorder
depressive symptoms
high dose
open label
clinical trial
emergency department
human health
type diabetes
risk assessment
low dose
insulin resistance